1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Gencurix, Inc.

Gencurix, Inc.

KKRX:229000
1,957.00
KRW
+17.00
(+0.88%)
-379.83EPS
51.66BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.31
45.62
23.08
242.47
426.3
283.38
219.97
346.86
472.13
451.85
Basic EPS, GAAP
-1,328.39
-1,035.02
-1,547.97
5,106.75
-4,850.73
-2,723.3
-1,629.25
-245
-462
-379.83
Free Cash Flow per Basic Share
-1,096.36
-1,022.53
-1,066.11
-2,298.36
-1,376.32
-2,601.66
-1,104.26
-535.96
-418.45
-201.8
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1,192.02
1,541.59
26.22
7,600.05
4,276.98
862.9
1,014.05
942.71
698.69
538.04
Tangible Book Value per Share
1,154.24
1,403.15
26.22
7,140.2
3,757.81
789.72
958.92
892.22
655.11
489.41
Basic Weighted Avg Shares
5
6
6
6
7
9
12
15
16
20
Sales/Revenue/Turnover
7
252
137
1,572
3,047
2,559
2,600
5,134
7,548
8,930
Operating Margin (%)
-94,010.08
-2,263.52
-4,801.54
-589.48
-418.29
-430.05
-429.12
-156.4
-78.83
-53.52
Depreciation Expense
530
585
869
114
432
914
1,391
1,476
1,376
1,362
Net Income, GAAP
-6,820
-5,724
-9,162
33,108
-34,670
-24,597
-19,260
-3,626
-7,386
-7,507
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-101,319.51
-2,268.73
-6,706.45
2,106.14
-1,137.86
-961.01
-740.68
-70.63
-97.85
-84.06
Working Capital
4,606
6,704
-685
2,560
353
-17,856
-2,019
-4,351
1,769
-9,441
LT Debt
- -
- -
309
603
238
3,999
4,688
1,359
198
169
Total Equity
6,406
9,124
155
53,911
31,042
5,673
12,003
14,897
16,369
12,605
Return on Invested Capital (%)
- -
- -
- -
-32.52
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
117.49
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-73.72
-197.47
123.7
-82.39
-132.59
-191.95
-25.31
-47.25
-62.36

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
9,722
10,518
10,698
LT Borrowings
54
56
59
LT Finance Leases
144
127
110
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
36,337
59,625
51,659

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
17,090
9,267
8,718
Cash, Cash Equivalents & STI
9,051
170
97
Accounts Receivable, Net
3,755
4,192
5,062
Inventories
529
631
521
Total Current Liabilities
15,322
16,697
18,159
Payables & Accruals
- -
- -
- -
ST Debt
9,722
10,518
10,698
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.28%
9.88%
Free Cash Flow
- -
1.11%
-15.66%
Net Income, GAAP
- -
-46.59%
103.69%
Sales/Revenue/Turnover
- -
44.78%
47.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
816
563
1,437
- -
5,134
2025
1,706
2,002
1,728
2,112
7,548
2026
2,101
2,989
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-227.1
-280.68
-124.18
- -
-245
2025
-126
-97
-126.18
-112.58
-462
2026
-101.19
-55
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sang-Rae Cho
Full Time Employees
75
Sector
Health technology
Industry
Medical specialties
Address
Hanhwa Bizmetro Seoul SL South Korea 152-733
IPO Date
Oct 27, 2015
Website
gencurix.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Gencurix Inc. (229000.KQ) develops and commercializes precision diagnostics solutions for oncology, focusing on molecular tests that enable personalized cancer treatment through companion diagnostics and prognostic assays. The company offers RevealDx RevealDx, a comprehensive genomic profiling service using next-generation sequencing (NGS) to detect actionable mutations, gene fusions, and biomarkers in solid tumors; XpertDx, a line of PCR-based assays including EGFR LiquidSense for liquid biopsy detection of EGFR mutations in non-small cell lung cancer (NSCLC), KRAS Dx for colorectal cancer, and ALK Dx for lung cancer rearrangements; and CE-marked IVD kits such as EGFR Reflex and KRAS Reflex for in vitro diagnostic use in Europe. These products support clinical decision-making across tumor types like lung, breast, colorectal, and prostate cancers, serving oncologists, pathologists, and pharmaceutical partners developing targeted therapies. Gencurix operates primarily in South Korea, with expanding presence in Europe and Asia through regulatory approvals and distribution agreements; the company was founded in 2001 and is headquartered in Seoul, South Korea. In recent developments, Gencurix launched its CE-marked XpertDx EGFR LiquidSense assay in Europe in 2024, enhancing its liquid biopsy portfolio for NSCLC monitoring; formed a strategic partnership with AstraZeneca Korea in 2024 to co-promote companion diagnostics; and expanded manufacturing capacity in 2025 to meet growing demand for NGS-based services amid rising adoption of precision oncology in Asia. [web:previous]